self injecting tirzepatide Injection At-Home Zepbound Tirzepatide Injection 5 mg/0.5

Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial

Discontinuation due to side effects ran from about 5% at 5 mg to about 10% at 15 mg

Consult professionals for personalized advice

Per il lettore italiano conta soprattutto il dato europeo: il 18 agosto 2025 la Commissione europea ha concesso a resmetirom (Rezdiffra) un autorizzazione condizionata valida in tutta lUnione , per gli adulti con MASH non cirrotica e fibrosi moderata-avanzata

Overview of NICE TA1026 Tirzepatide is recommended by NICE (2024) for managing obesity alongside a reduced-calorie diet and increased physical activity in adults, only if they have: An initial BMI of at least 35 kg/m 2 , and At least one weight-related comorbidity